Danaher
Market Cap
US$143.3b
Last Updated
2020/08/11 00:16 UTC
Data Sources
Company Financials +
Executive Summary
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
Snowflake Analysis
Solid track record with limited growth.
Similar Companies
Share Price & News
How has Danaher's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DHR has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.0%
DHR
-1.4%
US Medical Equipment
1.2%
US Market
1 Year Return
43.8%
DHR
14.9%
US Medical Equipment
16.8%
US Market
Return vs Industry: DHR exceeded the US Medical Equipment industry which returned 15.9% over the past year.
Return vs Market: DHR exceeded the US Market which returned 16.4% over the past year.
Shareholder returns
| DHR | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.0% | -1.4% | 1.2% |
| 30 Day | 10.0% | 7.8% | 4.9% |
| 90 Day | 26.4% | 11.7% | 20.0% |
| 1 Year | 44.4%43.8% | 15.9%14.9% | 19.3%16.8% |
| 3 Year | 155.0%150.8% | 72.7%68.1% | 43.7%34.4% |
| 5 Year | 199.8%120.8% | 116.8%100.0% | 75.5%56.6% |
Price Volatility Vs. Market
How volatile is Danaher's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Have Insiders Sold Danaher Corporation (NYSE:DHR) Shares Recently?2 weeks ago | Simply Wall St
Danaher Corporation's (NYSE:DHR) Stock Is Going Strong: Have Financials A Role To Play?4 weeks ago | Simply Wall St
Did Danaher Corporation (NYSE:DHR) Insiders Buy Up More Shares?Valuation
Is Danaher undervalued compared to its fair value and its price relative to the market?
50.24x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DHR ($202.05) is trading above our estimate of fair value ($182.79)
Significantly Below Fair Value: DHR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DHR is good value based on its PE Ratio (50.2x) compared to the US Medical Equipment industry average (51.9x).
PE vs Market: DHR is poor value based on its PE Ratio (50.2x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: DHR is poor value based on its PEG Ratio (3.1x)
Price to Book Ratio
PB vs Industry: DHR is overvalued based on its PB Ratio (4.3x) compared to the US Medical Equipment industry average (3.9x).
Next Steps
Future Growth
How is Danaher forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
16.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DHR's forecast earnings growth (16.2% per year) is above the savings rate (2.2%).
Earnings vs Market: DHR's earnings (16.2% per year) are forecast to grow slower than the US market (23.7% per year).
High Growth Earnings: DHR's earnings are forecast to grow, but not significantly.
Revenue vs Market: DHR's revenue (9.4% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: DHR's revenue (9.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DHR's Return on Equity is forecast to be low in 3 years time (12.2%).
Next Steps
Past Performance
How has Danaher performed over the past 5 years?
6.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DHR has high quality earnings.
Growing Profit Margin: DHR's current net profit margins (15.1%) are higher than last year (13.4%).
Past Earnings Growth Analysis
Earnings Trend: DHR's earnings have grown by 6.5% per year over the past 5 years.
Accelerating Growth: DHR's earnings growth over the past year (33%) exceeds its 5-year average (6.5% per year).
Earnings vs Industry: DHR earnings growth over the past year (33%) exceeded the Medical Equipment industry 1.2%.
Return on Equity
High ROE: DHR's Return on Equity (8.1%) is considered low.
Next Steps
Financial Health
How is Danaher's financial position?
Financial Position Analysis
Short Term Liabilities: DHR's short term assets ($12.3B) exceed its short term liabilities ($5.6B).
Long Term Liabilities: DHR's short term assets ($12.3B) do not cover its long term liabilities ($29.4B).
Debt to Equity History and Analysis
Debt Level: DHR's debt to equity ratio (61.3%) is considered high.
Reducing Debt: DHR's debt to equity ratio has increased from 14.2% to 61.3% over the past 5 years.
Debt Coverage: DHR's debt is not well covered by operating cash flow (19.5%).
Interest Coverage: DHR's interest payments on its debt are well covered by EBIT (97.6x coverage).
Balance Sheet
Next Steps
Dividend
What is Danaher current dividend yield, its reliability and sustainability?
0.36%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DHR's dividend (0.36%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.62%).
High Dividend: DHR's dividend (0.36%) is low compared to the top 25% of dividend payers in the US market (4.35%).
Stability and Growth of Payments
Stable Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: DHR is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DHR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.6yrs
Average management tenure
CEO
Tom Joyce (59 yo)
5.92yrs
Tenure
US$18,193,200
Compensation
Mr. Thomas P. Joyce, Jr., also known as Tom, has been the Chief Executive Officer and President of Danaher Corp. since September 9, 2014. Mr. Joyce serves as a Director of MedStar Health, Inc. Mr. Joyce se ...
CEO Compensation Analysis
Compensation vs Market: Tom's total compensation ($USD18.19M) is above average for companies of similar size in the US market ($USD11.30M).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 36.58yrs | no data | 6.08% $ 8.7b | |
| CEO, President & Director | 5.92yrs | US$18.19m | 0.029% $ 42.1m | |
| Co-Founder & Director | 37.58yrs | no data | 5% $ 7.2b | |
| CFO & Executive VP | 1.58yrs | US$4.59m | 0.0030% $ 4.3m | |
| Executive Vice President | 3.58yrs | US$7.18m | 0.0051% $ 7.3m | |
| Executive Vice President | 2.67yrs | US$6.36m | 0.013% $ 18.7m | |
| Chief Accounting Officer & Senior VP | 10.5yrs | no data | 0.0027% $ 3.8m | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP | 4.58yrs | US$3.71m | 0.0035% $ 5.0m | |
| Senior Vice President of Corporate Development | 10.5yrs | no data | 0.0028% $ 4.0m | |
| Senior Vice President of Human Resources | 8.33yrs | US$3.90m | 0.0051% $ 7.3m | |
| Executive Vice President | 1.58yrs | US$6.85m | 0.020% $ 28.1m |
4.6yrs
Average Tenure
56yo
Average Age
Experienced Management: DHR's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 36.58yrs | no data | 6.08% $ 8.7b | |
| CEO, President & Director | 5.92yrs | US$18.19m | 0.029% $ 42.1m | |
| Co-Founder & Director | 37.58yrs | no data | 5% $ 7.2b | |
| Independent Director | 21.58yrs | US$299.08k | 0.011% $ 15.5m | |
| Independent Director | 37.58yrs | US$317.08k | 0.060% $ 86.4m | |
| Independent Director | 17.08yrs | US$344.08k | 0.0034% $ 4.8m | |
| Independent Director | 11.58yrs | US$335.08k | 0.0024% $ 3.4m | |
| Independent Director | 3.5yrs | US$299.08k | no data | |
| Lead Independent Director | 0.25yr | US$335.08k | 0.0054% $ 7.7m | |
| Independent Director | 8.92yrs | US$299.08k | no data | |
| Independent Director | 0.75yr | US$105.01k | no data | |
| Independent Director | 0.75yr | US$105.01k | no data |
10.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: DHR's board of directors are seasoned and experienced ( 10.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DHR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Danaher Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Danaher Corporation
- Ticker: DHR
- Exchange: NYSE
- Founded: 1969
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$143.336b
- Shares outstanding: 709.41m
- Website: https://www.danaher.com
Number of Employees
Location
- Danaher Corporation
- 2200 Pennsylvania Avenue NW
- Suite 800W
- Washington
- District Of Columbia
- 20037-1701
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| DHR | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Nov 1969 |
| DAP | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 1969 |
| DAP | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Nov 1969 |
| DHR * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Nov 1969 |
| DHR | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Nov 1969 |
| 0R2B | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Nov 1969 |
| DAP | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Nov 1969 |
| DHRC | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Nov 1969 |
| DHER34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 4 REPR 1 COM SHS USD0.01 | BR | BRL | Jul 2015 | |
| DHR.PRA | NYSE (New York Stock Exchange) | 4.75 MND CV PFD | US | USD | Feb 2019 | |
| DHR.PRB | NYSE (New York Stock Exchange) | 5% CONV PFD B | US | USD | May 2020 |
Biography
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnos ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/11 00:16 |
| End of Day Share Price | 2020/08/10 00:00 |
| Earnings | 2020/07/03 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.